experimental vaccine - The African Mirror

Oct

2022

Serum Institute to produce Ebola vaccine for use in Uganda outbreak

AARON ROSS THE Serum Institute of India plans to manufacture 20,000 to 30,000 doses of an experimental Ebola vaccine by the end of November for use in trials against an outbreak in Uganda, its developers and a company source said. The response to Uganda's outbreak has been blunted by the absence of a proven vaccine against the Sudan strain of the virus. There have been 54 confirmed cases and 19 deaths since last month and the first case in the capital, Kampala, was recorded last week. But health authorities believe the actual numbers could be higher. Vaccines against the more common Zaire…

Nov

2020

By The African Mirror

Global reaction to Moderna says its vaccine is 94.5% effective in preventing COVID-19

COVID-19

MODERNA has revealed that its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second U.S. company in a week to report results that far exceed expectations. Following are reactions to the news. WALID GELLAD, PROFESSOR OF MEDICINE, UNIVERSITY OF PITTSBURGH, PENNSYLVANIA "Now we know that the vaccine appears to be highly effective. It also seems like we really need the vaccine right now, because we have no coherent national strategy. And the next two months are looking dismal. So there, there has to be some willingness for uncertainty and…

Sep

2020

By The African Mirror

AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illness

COVID-19

MICHAEL HOLDEN ASTRAZENECA has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs, the company has announced. The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended this week after an illness in a study subject in Britain, casting doubts on an early rollout. "On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators," AstraZeneca said. It added that safety…